Yen‐Hwa Chang

机构：National Yang Ming Chiao Tung University, Taipei Veterans General Hospital

发表论文 70 篇 · 总被引 7454 次 · h-index 21

代表论文

• Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma (2021 · New England Journal of Medicine · 被引 766)
• Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial (2021 · The Lancet Oncology · 被引 655)
• Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial (2022 · The Lancet Oncology · 被引 285)
• Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study (2023 · European Urology · 被引 140)
• Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for patients with renal cell carcinoma: Randomized, double-blind, phase III KEYNOTE-564 study. (2021 · Journal of Clinical Oncology · 被引 38)
• Pembrolizumab for advanced urothelial carcinoma: exploratory ctDNA biomarker analyses of the KEYNOTE-361 phase 3 trial (2024 · Nature Medicine · 被引 35)